Drug Characteristics
  • Formulation

    100mg tablets

    250mg tablets

    Co formulated with lamivudine as Combivir

    Co formulated with lamivudine and Abacavir as Trizivir

  • Dose

    250mg twice daily


    Oral Term (>34 weeks): 4 mg/kg twice daily

    Premature (30–34 weeks): 2 mg/kg twice daily for 2 weeks then 2 mg/kg three times a day for 2 weeks

    Premature (<30 weeks):  2 mg/kg twice daily for 4 weeks


    Term: 1.5 mg/kg four times a day

    Prem: 1.5 mg/kg twice daily

  • Side Effects

    myelosuppression, anaemia, nail pigmentation 

  • Interactions
  • Renal

    reduce oral dose to 300–400 mg daily in divided doses or intravenous dose to 1 mg/kg 3–4 times daily if eGFR is less than 10 mL/minute/1.73 m2

  • Hepatic
  • Pregnancy

    FDA Pregnancy Category C status

    indicated for the prevention of maternal-fetal HIV-1 transmission.

  • Other Information